Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Sunshine Biopharma (SBFM) over the last 12 years, with Q3 2025 value amounting to $253.0.

  • Sunshine Biopharma's Other Non Operating Income fell 9833.04% to $253.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$337359.0, marking a year-over-year decrease of 21401.81%. This contributed to the annual value of -$44082.0 for FY2024, which is 1789265.31% down from last year.
  • Sunshine Biopharma's Other Non Operating Income amounted to $253.0 in Q3 2025, which was down 9833.04% from $1940.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Other Non Operating Income ranged from a high of $286535.0 in Q2 2024 and a low of -$340003.0 during Q4 2024
  • Its 5-year average for Other Non Operating Income is $1123.1, with a median of $130.5 in 2021.
  • Data for Sunshine Biopharma's Other Non Operating Income shows a peak YoY increase of 10988352.49% (in 2024) and a maximum YoY decrease of 87170256.41% (in 2024) over the last 5 years.
  • Sunshine Biopharma's Other Non Operating Income (Quarter) stood at -$7909.0 in 2021, then surged by 100.32% to $25.0 in 2022, then tumbled by 256.0% to -$39.0 in 2023, then plummeted by 871702.56% to -$340003.0 in 2024, then skyrocketed by 100.07% to $253.0 in 2025.
  • Its last three reported values are $253.0 in Q3 2025, $1940.0 for Q2 2025, and $451.0 during Q1 2025.